Disruptive Pharma raises 27 million SEK to conduct clinical study on its improved sorafenib product DPH001 and to nominate second product candidate

PRESS RELEASE / PRESSMEDDELANDE
Disruptive Pharma offentliggör utfall i företrädesemission av aktier 2024-04-25

“It is a sign of strength that we have been able to successfully complete this rights issue in a challenging market. We now have sufficient funds to advanced our innovative first product DPH001 through clinical proof-of-concept and nominating a second product candidate within the next 12 months, thus transforming Disruptive Pharma from a research company into a clinical stage pharmaceutical company. I want to extend a warm thank you to all long-term shareholders and new investors for your trust.” comments Peter Åsberg, CEO of Disruptive Pharma.